Suggested remit: To appraise the clinical and cost effectiveness of bimekizumab within its marketing authorisation for treating moderate to severe hidradenitis suppurativa
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6134

Provisional Schedule

Committee meeting: 1 11 September 2024
Expected publication 20 November 2024

Project Team

Project lead Thomas Feist

Email enquiries

External Assessment Group Centre for Reviews and Dissemination and Centre for Health Economics, University of York


Companies sponsors UCB Pharma
Others Department of Health and Social Care
  NHS England
Professional groups British Association of Dermatologists
  Royal College of Physicians
Comparator companies Novartis
General commentators All Wales Therapeutics and Toxicology Centre
  Board of Community Health Councils in Wales
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Health Specialised Services


Key events during the development of the guidance:

Date Update
12 February 2024 Invitation to participate
19 October 2023 Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in mid-February 2024. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission.
24 March 2023 - 25 April 2023 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
24 March 2023 In progress. Scoping commenced
16 May 2022 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual